+12.0%
ABBV vs MRNA
+154.4%
-142.4%
-12.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.9% | -3.4% | +4.2% | +0.9% |
| 7D | -4.1% | -10.1% | +5.9% | -3.9% |
| 30D | +1.2% | +126.7% | -125.5% | -1.3% |
| 3M | +12.1% | +184.1% | -172.0% | +7.6% |
| 6M | +12.0% | +143.3% | -131.3% | +9.9% |
| All | +12.0% | +154.4% | -142.4% | +9.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling